Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Pliant Therapeutics, Inc.
Jonsson Comprehensive Cancer Center
West China Hospital
Actym Therapeutics, Inc.
Toray Industries, Inc
Eli Lilly and Company
ABM Therapeutics Shanghai Company Limited
NGM Biopharmaceuticals, Inc
University of California, San Diego
ABM Therapeutics Corporation
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Xencor, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
AbbVie
AbbVie
Fore Biotherapeutics